Ularitide

Drug Profile

Ularitide

Alternative Names: ANF-95-126; ANP 95126; Atrial natriuretic factor (95-126); Atrial natriuretic factor prohormone (95-126); Atriopeptin (95-126); CDD 95-126; CDD ANP 95-126; ESP-305; Ularitide acetate; Urodilatin

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator CardioPep Pharma; University of Heidelberg
  • Developer Cardiorentis; PDL BioPharma
  • Class Amino acids; Natriuretic peptides
  • Mechanism of Action Atrial peptide agonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute heart failure
  • Discontinued Asthma; Kidney disorders

Most Recent Events

  • 19 Jun 2017 Ularitide is still at phase III development stage for Acute heart failure in Canada, Israel, Latin America, European Union, Serbia, Switzerland, Turkey and USA (IV) (Cardiorentis website, June 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Mar 2016 Cardiorentis completes the TRUE-AHF trial in (Acute heart failure in USA, Argentina, Belgium, Brazil, Chile, Canada, Germany, Israel, France, Poland, Romania, Serbia, Switzerland, Turkey, Sweden, Czech Republic, Spain, Latvia, Lithuania, Estonia, Italy, Finland, the Netherlands and Hungary (NCT01661634)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top